Schrödinger, Inc. (SDGR)

US — Healthcare Sector
Peers: TDOC  VEEV  TXG  GEHC  PGNY  BEAM  TWST  NTLA  CRSP 

Automate Your Wheel Strategy on SDGR

With Tiblio's Option Bot, you can configure your own wheel strategy including SDGR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol SDGR
  • Rev/Share 3.2402
  • Book/Share 4.6695
  • PB 4.1931
  • Debt/Equity 0.3334
  • CurrentRatio 3.2997
  • ROIC -0.3535

 

  • MktCap 1441205500.0
  • FreeCF/Share 0.3319
  • PFCF 59.1361
  • PE -7.9286
  • Debt/Assets 0.1661
  • DivYield 0
  • ROE -0.457

 

  • Rating C-
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 2
  • D/E Score 2

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Downgrade SDGR Citigroup Buy Neutral -- $20 Aug. 15, 2025
Initiation SDGR Barclays -- Overweight -- $25 Aug. 14, 2025
Resumed SDGR Morgan Stanley -- Equal Weight -- $28 July 3, 2025

News

3 Momentum Stocks That Could Soar Post-Market Volatility
CERT, LOVE, SDGR
Published: April 21, 2025 by: MarketBeat
Sentiment: Negative

While the impact of unanticipated tariff policy changes in early April was market-wide, the recovery has been less even. Despite a major rebound following the sell-off, some firms have been sluggish to reclaim lost ground.

Read More
image for news 3 Momentum Stocks That Could Soar Post-Market Volatility
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SDGR
Published: April 18, 2025 by: Business Wire
Sentiment: Neutral

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on April 16, 2025, the company granted (i) a non-statutory stock option to purchase 3,300 shares of the company's common stock to one newly hired employee and (ii) restricted stock units (RSUs) with respect to 12,866 shares of the company's common stock to six newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of.

Read More
image for news Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Schrodinger, Inc. (SDGR) Reports Q4 Loss, Tops Revenue Estimates
SDGR
Published: February 26, 2025 by: Zacks Investment Research
Sentiment: Negative

Schrodinger, Inc. (SDGR) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.32 per share a year ago.

Read More
image for news Schrodinger, Inc. (SDGR) Reports Q4 Loss, Tops Revenue Estimates

About Schrödinger, Inc. (SDGR)

  • IPO Date 2020-02-06
  • Website https://www.schrodinger.com
  • Industry Medical - Healthcare Information Services
  • CEO Ramy Farid
  • Employees 891

Schrödinger, Inc., together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.